CSL EBITDA 2017-2024 | CSLLY

CSL EBITDA for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • CSL 2024 EBITDA was 4.75B, a 21.79% increase from 2023.
  • CSL 2023 EBITDA was 3.9B, a 8.48% increase from 2022.
  • CSL 2022 EBITDA was 3.595B, a 3.35% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

CSL EBITDA 2017-2024 | CSLLY

  • CSL 2024 EBITDA was 4.75B, a 21.79% increase from 2023.
  • CSL 2023 EBITDA was 3.9B, a 8.48% increase from 2022.
  • CSL 2022 EBITDA was 3.595B, a 3.35% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$225.3B
Amgen (AMGN)$164.8B
Gilead Sciences (GILD)$144.5B
Vertex Pharmaceuticals (VRTX)$120.6B
Bristol Myers Squibb (BMY)$98.6B
GSK (GSK)$77.7B
Regeneron Pharmaceuticals (REGN)$60.8B
Alnylam Pharmaceuticals (ALNY)$42.9B
Argenex SE (ARGX)$36.2B
BioNTech SE (BNTX)$27.7B
Royalty Pharma (RPRX)$20.6B
Insmed (INSM)$19.7B
Biogen (BIIB)$19.3B
Illumina (ILMN)$17.3B
Genmab (GMAB)$15B
Genmab (GNMSF)$15B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.2B
Exelixis (EXEL)$12.4B
QIAGEN (QGEN)$11.5B
BioMarin Pharmaceutical (BMRN)$11.3B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.2B
Bio-Techne Corp (TECH)$9.2B
Exact Sciences (EXAS)$9.1B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$8B
Roivant Sciences (ROIV)$7.9B
Anbio Biotechnology (NNNN)$7.3B